Kinetic modeling of 3'-deoxy-3'-fluorothymidine in somatic tumors: mathematical studies.

UNLABELLED We present a method to measure the regional rate of cellular proliferation using a positron-emitting analog of thymidine (TdR) for human imaging studies. The method is based on the use of 3'-deoxy-3'-(18)F-fluorothymidine (FLT) to estimate the flux of TdR through the exogenous pathway. The model reflects the retention of FLT-monophosphate (FLTMP), which is generated by the phosphorylation of FLT by thymidine kinase 1 (TK1), the initial step in the exogenous pathway. METHODS A model of FLT kinetics has been designed based on the assumptions of a steady-state synthesis and incorporation of nucleotides into DNA, an equilibration of the free nucleoside in tissue with the plasma level, and the relative rates of FLT and TdR phosphorylation from prior data using direct analysis with in vitro assays. A 2-compartment model with 4 rate constants adequately describes the kinetics of FLT uptake and retention over 120 min and leads to an estimation of the rate of cellular proliferation using the measured FLT blood clearance and the dynamic FLT uptake curve. RESULTS Noise characteristics of kinetic parameter estimates for 3 tissues were assessed under a range of conditions representative of human cancer patient imaging. The FLT flux in these tissues can be measured with a SE of <5%, and FLT transport can be estimated with a SE of <15%. Abbreviating the data collection to 60 min or neglecting k(4), giving a 3-parameter model, results in an unsatisfactory loss of accuracy in the flux constant in tumor simulations. CONCLUSION These analyses depict model behavior and provide expected values for the accuracy of parameter estimates from FLT imaging in human patients. Our companion paper describes the performance of the model for human data in patients with lung cancer. Further studies are necessary to determine the fidelity of K(FLT) (FLT flux) as a proxy for K(TDR) (thymidine flux), the gold standard for imaging cellular proliferation.

[1]  T K Lewellen,et al.  Carbon-11-thymidine and FDG to measure therapy response. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  S. Yao,et al.  The equilibrative nucleoside transporter family, SLC29 , 2004, Pflügers Archiv.

[3]  A. Shields,et al.  Development of labeled thymidine analogs for imaging tumor proliferation. , 1996, Nuclear medicine and biology.

[4]  O. Muzik,et al.  Kinetics of 3'-deoxy-3'-[F-18]fluorothymidine uptake and retention in dogs. , 2002, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[5]  P. Reichard,et al.  Cytosolic High K m 5′-Nucleotidase and 5′(3′)-Deoxyribonucleotidase in Substrate Cycles Involved in Nucleotide Metabolism* , 2001, The Journal of Biological Chemistry.

[6]  D. Visvikis,et al.  Comparison of methodologies for the in vivo assessment of 18FLT utilisation in colorectal cancer , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  A. Buck,et al.  Fluoro-3-Deoxythymidine ( [ 18 F ]-FLT ) as Positron Emission Tomography Tracer for Imaging Proliferation in a Murine B-Cell Lymphoma Model and in the Human Disease , 2003 .

[8]  Conrad C. Huang,et al.  Functional and genetic diversity in the concentrative nucleoside transporter, CNT1, in human populations. , 2004, Molecular pharmacology.

[9]  M. Muzi,et al.  Metabolism of 3'-deoxy-3'-[F-18]fluorothymidine in proliferating A549 cells: validations for positron emission tomography. , 2004, Nuclear medicine and biology.

[10]  C. R. Crawford,et al.  Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. , 1998, Cancer research.

[11]  T. Chou,et al.  Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-azido-3'-deoxythymidine , 1992, Antimicrobial Agents and Chemotherapy.

[12]  F. O’Sullivan,et al.  Kinetic Analysis of 2-[11C]Thymidine PET Imaging Studies of Malignant Brain Tumors: Compartmental Model Investigation and Mathematical Analysis , 2002 .

[13]  D. Mankoff,et al.  Kinetic analysis of 2-[11C]thymidine PET imaging studies: validation studies. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  J. Sherley,et al.  Regulation of human thymidine kinase during the cell cycle. , 1988, The Journal of biological chemistry.

[15]  J B Bassingthwaighte,et al.  Sensitivity functions in the estimation of parameters of cellular exchange. , 1984, Federation proceedings.

[16]  G A Ojemann,et al.  Glucose metabolism in human malignant gliomas measured quantitatively with PET, 1-[C-11]glucose and FDG: analysis of the FDG lumped constant. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  B. Oberg,et al.  Comparison of the substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs. , 1991, Biochemical and biophysical research communications.

[18]  M. Berger,et al.  2-[C-11]thymidine imaging of malignant brain tumors. , 1999, Cancer research.

[19]  D. Mankoff,et al.  Kinetic analysis of 2-[carbon-11]thymidine PET imaging studies: compartmental model and mathematical analysis. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  I Lemahieu,et al.  [Methyl-11C]thymidine positron emission tomography in tumoral and non-tumoral cerebral lesions. , 1999, Acta neurologica Belgica.

[21]  A Gelman,et al.  The Precision of Positron Emission Tomography: Theory and Measurement , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[22]  Mark Muzi,et al.  Kinetic analysis of 3'-deoxy-3'-fluorothymidine PET studies: validation studies in patients with lung cancer. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  L. Wiens,et al.  Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  K. Krohn,et al.  Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  D. Goldman,et al.  Some considerations in the experimental approach to distinguishing between membrane transport and intracellular disposition of antineoplastic agents, with specific reference to fluorodeoxyuridine, actinomycin D, and methotrexate. , 1981, Cancer treatment reports.

[26]  G. Glatting,et al.  Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 3'-[18F]fluoro-3'-deoxythymidine ([18F]FLT) in pancreatic cancer cell lines , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[27]  M. Graham,et al.  Kinetic characterization of hexokinase isoenzymes from glioma cells: implications for FDG imaging of human brain tumors. , 2001, Nuclear medicine and biology.

[28]  J. Cleaver.  The relationship between the rate of DNA synthesis and its inhibition by ultraviolet light in mammalian cells. , 1967, Radiation research.

[29]  C. R. Crawford,et al.  Nucleoside transport in normal and neoplastic cells. , 1993, Advances in enzyme regulation.

[30]  A. Shields,et al.  Radiosyntheses of labeled beta-pseudothymidine ([C-11]- and [H-3]methyl) and its biodistribution and metabolism in normal and tumored mice. , 1995, Nuclear medicine and biology.

[31]  B. Oberg,et al.  Antiviral effects of 3'-fluorothymidine and 3'-azidothymidine in cynomolgus monkeys infected with simian immunodeficiency virus. , 1991, Journal of acquired immune deficiency syndromes.

[32]  F. O’Sullivan,et al.  Kinetic analysis of 2-[11C]thymidine PET imaging studies of malignant brain tumors: preliminary patient results. , 2002, Molecular imaging.

[33]  S M Larson,et al.  Positron imaging feasibility studies. I: Characteristics of [3H]thymidine uptake in rodent and canine neoplasms: concise communication. , 1981, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[34]  Janet F. Eary,et al.  Kinetic Analysis of 2-[11C]Thymidine PET Imaging Studies of Malignant Brain Tumors: Preliminary Patient Results , 2002 .

[35]  H. Thierens,et al.  Kinetics of [methyl-11C]thymidine in patients with squamous cell carcinoma of the head and neck. , 1996, Acta oncologica.

[36]  F. O’Sullivan,et al.  Metabolic images from dynamic positron emission tomography studies , 1994, Statistical methods in medical research.

[37]  Sven N Reske,et al.  3'-[18F]fluoro-3'-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease. , 2003, Cancer research.

[38]  Thomas K Lewellen,et al.  18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[39]  M. Reivich,et al.  THE [14C]DEOXYGLUCOSE METHOD FOR THE MEASUREMENT OF LOCAL CEREBRAL GLUCOSE UTILIZATION: THEORY, PROCEDURE, AND NORMAL VALUES IN THE CONSCIOUS AND ANESTHETIZED ALBINO RAT 1 , 1977, Journal of neurochemistry.

[40]  S. Eriksson,et al.  Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides. , 1991, The Journal of biological chemistry.